Aspen Pharmacare Holdings Ltd
JSE:APN
Net Margin
Aspen Pharmacare Holdings Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| ZA |
A
|
Aspen Pharmacare Holdings Ltd
JSE:APN
|
52.2B Zac |
10%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
719.1B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
401.6B USD |
25%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
204.5B CHF |
14%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
172.2B GBP |
15%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
182.3B CHF |
25%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
35%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
198.7B USD |
26%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
133.3B USD |
13%
|
Aspen Pharmacare Holdings Ltd
Glance View
In the vibrant world of global pharmaceuticals, Aspen Pharmacare Holdings Ltd. stands out as a beacon of South African innovation and business acumen. Founded in Durban in 1997, Aspen has grown from modest beginnings into a multinational powerhouse. The company’s core strength lies in manufacturing and producing a diversified portfolio of pharmaceutical products, including generic medications, branded pharmaceuticals, and over-the-counter consumer health products. It further engages in anesthetics, nutritional products, and critical care drugs, offering solutions to myriad health challenges across more than 50 countries. This diversification not only ensures a broad market appeal but effectively hedges against the risks inherent in the pharmaceutical sector, such as patent expirations and regulatory hurdles. Aspen’s financial blueprint is designed around strategic partnerships and manufacturing competencies that serve both developed and emerging markets. It generates revenue primarily through its extensive distribution network and its ability to produce cost-effective generics that address high-demand therapeutic areas, such as cardiovascular, diabetes, and cancer treatments. The company’s growth is fuelled by both organic expansion and astute acquisitions, such as the incorporation of select portfolios from global giants like GlaxoSmithKline. Aspen meticulously balances manufacturing efficiency with stringent regulatory compliance, operated through state-of-the-art facilities accredited by international regulatory bodies. By maintaining this commitment to quality and cost-efficiency, Aspen differentiates itself from competitors and consolidates its position as a significant player in the global pharmaceutical landscape.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Aspen Pharmacare Holdings Ltd's most recent financial statements, the company has Net Margin of 9.8%.
You don't have any saved screeners yet